Literature DB >> 24142589

The treatment of tremor.

Susanne A Schneider1, Günther Deuschl.   

Abstract

Tremor is a hyperkinetic movement disorder characterized by rhythmic oscillations of one or more body parts. It can be disabling and may impair quality of life. Various etiological subtypes of tremor are recognized, with essential tremor (ET) and Parkinsonian tremor being the most common. Here we review the current literature on tremor treatment regarding ET and head and voice tremor, as well as dystonic tremor, orthostatic tremor, tremor due to multiple sclerosis (MS) or lesions in the brainstem or thalamus, neuropathic tremor, and functional (psychogenic) tremor, and summarize main findings. Most studies are available for ET and only few studies specifically focused on other tremor forms. Controlled trials outside ET are rare and hence most of the recommendations are based on a low level of evidence. For ET, propranolol and primidone are considered drugs of first choice with a mean effect size of approximately 50 % tremor reduction. The efficacy of topiramate is also supported by a large double-blind placebo-controlled trial, while other drugs have less supporting evidence. With a mean effect size of about 90 % deep brain stimulation in the nucleus ventralis intermedius or the subthalamic nucleus may be the most potent treatment; however, there are no controlled trials and it is reserved for severely affected patients. Dystonic limb tremor may respond to anticholinergics. Botulinum toxin improves head and voice tremor. Gabapentin and clonazepam are often recommended for orthostatic tremor. MS tremor responds only poorly to drug treatment. For patients with severe MS tremor, thalamic deep brain stimulation has been recommended. Patients with functional tremor may benefit from antidepressants and are best be treated in a multidisciplinary setting. Several tremor syndromes can already be treated with success. But new drugs specifically designed for tremor treatment are needed. ET is most likely covering different entities and their delineation may also improve treatment. Modern study designs and long-term studies are needed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24142589      PMCID: PMC3899476          DOI: 10.1007/s13311-013-0230-5

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  140 in total

1.  Levetiracetam in primary orthostatic tremor: a double-blind placebo-controlled crossover study.

Authors:  Helge Hellriegel; Jan Raethjen; G Deuschl; Jens Volkmann
Journal:  Mov Disord       Date:  2011-09-23       Impact factor: 10.338

2.  beta-Adrenoreceptor antagonists in essential tremor.

Authors:  D Jefferson; P Jenner; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-10       Impact factor: 10.154

3.  [Orthostatic tremor: clinical aspects, pathophysiology and therapy].

Authors:  G Deuschl; C H Lücking; J Quintern
Journal:  EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb       Date:  1987-03

4.  MR-guided focused ultrasound thalamotomy for essential tremor: a proof-of-concept study.

Authors:  Nir Lipsman; Michael L Schwartz; Yuexi Huang; Liesly Lee; Tejas Sankar; Martin Chapman; Kullervo Hynynen; Andres M Lozano
Journal:  Lancet Neurol       Date:  2013-03-21       Impact factor: 44.182

5.  Blinded placebo crossover study of gabapentin in primary orthostatic tremor.

Authors:  Julian P Rodrigues; Dylan J Edwards; Susan E Walters; Michelle L Byrnes; Gary W Thickbroom; Rick Stell; Frank L Mastaglia
Journal:  Mov Disord       Date:  2006-07       Impact factor: 10.338

6.  Atenolol vs. propranolol in essential tremor. A controlled, quantitative study.

Authors:  T A Larsen; H Teräväinen; D B Calne
Journal:  Acta Neurol Scand       Date:  1982-11       Impact factor: 3.209

Review 7.  Essential tremor--neurodegenerative or nondegenerative disease towards a working definition of ET.

Authors:  Günther Deuschl; Rodger Elble
Journal:  Mov Disord       Date:  2009-10-30       Impact factor: 10.338

8.  Gamma Knife thalamotomy for essential tremor.

Authors:  Douglas Kondziolka; Joseph G Ong; John Y K Lee; Robert Y Moore; John C Flickinger; L Dade Lunsford
Journal:  J Neurosurg       Date:  2008-01       Impact factor: 5.115

Review 9.  Psychogenic movement disorders.

Authors:  Amitabh Gupta; Anthony E Lang
Journal:  Curr Opin Neurol       Date:  2009-08       Impact factor: 5.710

10.  Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease.

Authors:  Alessio Di Fonzo; Cristina Tassorelli; Michele De Mari; Hsin F Chien; Joaquim Ferreira; Christan F Rohé; Giulio Riboldazzi; Angelo Antonini; Gianni Albani; Alessandro Mauro; Roberto Marconi; Giovanni Abbruzzese; Leonardo Lopiano; Emiliana Fincati; Marco Guidi; Paolo Marini; Fabrizio Stocchi; Marco Onofrj; Vincenzo Toni; Michele Tinazzi; Giovanni Fabbrini; Paolo Lamberti; Nicola Vanacore; Giuseppe Meco; Petra Leitner; Ryan J Uitti; Zbigniew K Wszolek; Thomas Gasser; Erik J Simons; Guido J Breedveld; Stefano Goldwurm; Gianni Pezzoli; Cristina Sampaio; Egberto Barbosa; Emilia Martignoni; Ben A Oostra; Vincenzo Bonifati
Journal:  Eur J Hum Genet       Date:  2006-03       Impact factor: 4.246

View more
  13 in total

1.  Editorial: Neurotherapeutics of movement disorders.

Authors:  Stewart A Factor; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

2.  MR Imaging of the Brain in Neurologic Wilson Disease.

Authors:  X-E Yu; S Gao; R-M Yang; Y-Z Han
Journal:  AJNR Am J Neuroradiol       Date:  2019-01       Impact factor: 3.825

3.  β-Adrenoceptor Blockade Moderates Neuroinflammation in Male and Female EAE Rats and Abrogates Sexual Dimorphisms in the Major Neuroinflammatory Pathways by Being More Efficient in Males.

Authors:  Ivan Pilipović; Zorica Stojić-Vukanić; Ivana Prijić; Nebojša Jasnić; Jelena Djordjević; Gordana Leposavić
Journal:  Cell Mol Neurobiol       Date:  2022-07-08       Impact factor: 5.046

Review 4.  Cannabinoids and Tremor Induced by Motor-related Disorders: Friend or Foe?

Authors:  Shokouh Arjmand; Zohreh Vaziri; Mina Behzadi; Hassan Abbassian; Gary J Stephens; Mohammad Shabani
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 5.  The differential diagnosis and treatment of tremor.

Authors:  Kai Bötzel; Volker Tronnier; Thomas Gasser
Journal:  Dtsch Arztebl Int       Date:  2014-03-28       Impact factor: 5.594

Review 6.  Magnetic Resonance-Guided Focused Ultrasound Neurosurgery for Essential Tremor: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2018-05-03

7.  Approach to a tremor patient.

Authors:  Soumya Sharma; Sanjay Pandey
Journal:  Ann Indian Acad Neurol       Date:  2016 Oct-Dec       Impact factor: 1.383

8.  Botulinum Toxin for the Treatment of Hand Tremor.

Authors:  Nicki Niemann; Joseph Jankovic
Journal:  Toxins (Basel)       Date:  2018-07-19       Impact factor: 4.546

Review 9.  Non-invasive Central and Peripheral Stimulation: New Hope for Essential Tremor?

Authors:  Moussa A Chalah; Jean-Pascal Lefaucheur; Samar S Ayache
Journal:  Front Neurosci       Date:  2015-11-18       Impact factor: 4.677

Review 10.  Managing Essential Tremor.

Authors:  Franziska Hopfner; Günther Deuschl
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 6.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.